Nukava

Nukava is a clinical-stage biotechnology company focused on developing innovative therapies for immunological and inflammatory diseases, with a primary emphasis on dermatology. The company's lead program, NUK-001, is a potent and selective topical Janus kinase (JAK) inhibitor designed to treat conditions such as alopecia areata while minimizing systemic exposure. Founded by a team of experienced industry veterans from Amgen and Kythera Biopharmaceuticals, Nukava leverages deep expertise in drug development to address significant unmet needs in skin-related autoimmune disorders. The company is backed by prominent life science investors and continues to advance its pipeline of targeted small molecule therapeutics.